Weining Zhen is an Oncology physician affiliated with Susan Thompson Buffett Foundation. OpenAlex indexes 85 publications with 7,104 citations (h-index 30); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
988102 Nebraska Medical Ctr
Omaha, NE 681988102
Telephone
402-552-3844Registry record last updated 6 Jul 2011.
Clinical trials
- A Phase 1 Dose Escalation Study of GC4419 in Combination With Chemoradiation for Squamous Cell Cancer of the Head & Neck
Sponsor: Galera Therapeutics, Inc.
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
3 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Telix PharmaceuticalsProgram year20241 payment
- EMD Serono, Inc.Program year20232 payments
- AstraZeneca Pharmaceuticals LPProgram year20211 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cardiovascular
69.2%Antiarrhythmic69.2%Lidocaine Hcl Viscous100%Part D≥12 patientsNervous system
30.8%Opioid Agonist30.8%Oxycodone Hcl100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- NCCN Guidelines® Insights: Head and Neck Cancers, Version 2.2025
Journal of the National Comprehensive Cancer Network
2025 - NCCN Guidelines® Insights: Head and Neck Cancers, Version 1.2022
Journal of the National Comprehensive Cancer Network
2022 - Systemic inflammation is associated with inferior disease control and survival in stage III non-small cell lung cancer
Annals of Translational Medicine
2021 - Head and Neck Cancers, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology
Journal of the National Comprehensive Cancer Network
2020
Similar KOLs
Other experts from the same institution or the same specialty.
Carl June, MD
University of Pennsylvania
Christopher Benz, MD
Buck Institute for Research on Aging
Christina Fitzmaurice, MD
Gundersen Health System
Beth Karlan, MD
Cedars-Sinai Medical Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”